First‐in‐Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Issue 6 (17th April 2014)

• Record Type: Journal Article
• Authors: Flechner, S. M.; Mulgoankar, S.; Melton, L. B.; Waid, T. H.; Agarwal, A.; Miller, S. D.; Fokta, F.; Getts, M. T.; Frederick, T. J.; Herrman, J. J.; Puisis, J. P.; O'Toole, L.; Sung, R.; Shihab, F.; Wiseman, A. C.; Getts, D. R.
• Is Part Of: American journal of transplantation. Volume 14:Issue 6(2014:Jun.)
• Page Start: 1346
• Page End: 1355
• Publication Date: 2014-04-17
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ajt.12698
• Languages: English
• ISSNs: 1600-6135

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ajt12698-sec-0001" sec-type="section"> <p>TOL101 is a murine IgM mAb targeting the αβ TCR. Unlike other T cell targets, the αβ TCR has no known intracellular signaling domains and may provide a nonmitogenic target for T cell inactivation. We report the 6‐month Phase 2 trial data testing TOL101 in kidney transplantation. The study was designed to identify a dose that resulted in significant CD3 T cell modulation (&lt;25 T cell/mm³), to examine the safety and tolerability of TOL101 and to obtain preliminary efficacy information. Thirty‐six patients were enrolled and given 5–10 daily doses of TOL101; 33 patients completed dosing, while three discontinued after two doses due to a self‐limiting urticarial rash. Infusion adjustments, antihistamines, steroids and dose escalation of TOL101 reduced the incidence of the rash. Doses of TOL101 above 28 mg resulted in prolonged CD3 modulation, with rapid recovery observed 7 days after therapy cessation. There were no cases of patient or graft loss. Few significant adverse events were reported, with one nosocomial pneumonia. There were five biopsy‐confirmed acute cellular rejections (13.9%); however, no donor‐specific antibodies were detected. Overall TOL101 was well‐tolerated, supporting continued clinical development using the dose escalating 21–28–42–42–42 mg regimen.</p> </sec> </abstract>